Study | Febrile neutropenia | ||||||||
---|---|---|---|---|---|---|---|---|---|
Balducci [19] | Â | Combined CHOP and R-CHOP Q2W | Combined CHOP and R-CHOP Q3W | ||||||
<  65 years | 65–75 years | >  75 years | Overall | <  65 years | 65–75 years | >  75 years | Overall | ||
Any grade | 2 (6.3) | 1 (3.3) | – | 3 (4.8) | 0 (0) | 2 (2.6) | 1 (3.1) | 3 (2.2) | |
Grade ≥ 3 | 2 (6.3) | 1 (3.3) | – | 3 (4.8) | 0 (0) | 1 (1.3) | 1 (3.1) | 2 (1.5) | |
Bozzoli [20] |  | Total (n = 51) | Pegfilgrastim (n = 27) | Filgrastim (n = 24) | p value | ||||
FN per patient, n (%) | 9/51 (18) | 4/27 (15) | 5/24 (21) | 0.7 | |||||
FN per cycle, n (%) | 13/201 (6.5) | 6/105 (5.7) | 7/96 (7.2) | 0.8 | |||||
Donkor [21] |  | Pegfilgrastim < 14 days group (n = 126) | Pegfilgrastim > 14 days group (n = 25) | Filgrastim group (n = 90) | No CSF group (n = 295) | ||||
FN per cycle | 0 (0) | 0 (0) | 0 (0) | 2 (0.7) | |||||
Dragnev [22] |  | Filgrastim (n = 25) | Pegfilgrastim (n = 10) | p value | |||||
FN, n | 0 | 0 | p = 1.0 | ||||||
Hecht [23] | Â | Placebo | Pegfilgrastim | OR (95% CI) | |||||
Grade 3/4 FN, % | 8 | 2 | 0.27 (0.07–1.00); p = 0.04 | ||||||
Hendlera [24] | Â | Overall patients, n (%) | Group A | Group B | Group C | Group D | |||
Total treated, n (%) | 231 (100) | 84 (36.3) | 26 (11.3) | 64 (27.7) | 57 (24.7) 6 (10.5) | ||||
FN | 13 (5.6) | 3 (3.6) | 3 (11.5) | 1 (1.5) | |||||
Kourlaba [25] | Â | Filgrastim (95% CI) | Pegfilgrastim (95% CI) | p value | |||||
FN, % (95% CI) | 3.4 (2.0–5.3) | 4.3 (2.8–6.4) | p = 0.5 | ||||||
Kurbacher [26] |  | Pegfilgrastim (n = 27) | Lipegfilgrastim (n = 26) |  | |||||
FN, % | 2.2 | 0 | Â | ||||||
Lane [27] | Â | Pegfilgrastim | G-CSF | p value | |||||
FN, % | 29.0 | 37.9 | p = 0.16 | ||||||
Lugtenburg [28] | Â | R-CHOP-14 | R-CHOP-21 | Â | |||||
<  65 years (n = 241) | ≥ 65 years (n = 168) | <  65 years (n = 343) | ≥ 65 years (n = 363) | ||||||
FN (any cycle), % | 17 | 23 | 14 | 24 | |||||
PP per intervention, % | 54 | 58 | 17 | 32 | |||||
Patients treated with pegfilgrastim with FN, % | 9 | 13 | 2 | 8 | |||||
Ng [29] |  | CHOP-14 (n = 2) | CHOP-21 (n = 16) |  | |||||
Incidence of breakthrough FN, % | 3.3 | 22.2 | |||||||
Pinter [30] | Â | Pegfilgrastim, n (%) | Placebo, n (%) | Difference | OR | p value | Â | ||
Grade 3/4 FN | 10 (2.4) | 24 (5.7) | −3.3%(−6.6, −0.0) | 0.41 (0.19–0.86) | p = 0.014 | ||||
Grade 4 FN | 10 (2.4) | 15 (3.5) | −1.2%(−4.0, 1.7) | 0.66 (0.29–1.49) | p = 0.312 | ||||
Grade 3/4 FN in FOLFOX-treated patients | 2 (1.0) | 13 (6.3) | n/a | 0.15 (0.03–0.65) | n/a | ||||
Grade 3/4 FN in FOLFIRI-treated patients | 8 (3.7) | 11 (5.1) | n/a | 0.72 (0.28–1.83) | n/a | ||||
Grade 3/4 FN in low-dose patients | 3 (1.9) | 7 (4) | n/a | 0.46 (0.12–1.8) | n/a | ||||
Grade 3/4 FN in high-dose patients | 7 (2.7) | 17 (6.8) | n/a | 0.37 (0.15–0.92) | n/a | ||||
Skarlos [31] | Â | Filgrastim | Pegfilgrastim | p value | Â | ||||
FN, n (%) | 1 (1) | 14 (13) | p = 0.001 |